Abstract T MP24: Vagus Nerve Stimulation Improves Motor Function After Chronic Stroke in Adult Rats

Stroke ◽  
2015 ◽  
Vol 46 (suppl_1) ◽  
Author(s):  
Navid Khodaparast ◽  
Reema Casavant ◽  
Andrea Ruiz ◽  
Robert L Rennaker ◽  
Michael P Kilgard

Background: Stroke is the leading cause of serious long-term disability. Currently, there is no effective treatment for chronic stroke patients. Neuroplasticity within motor circuitry is believed to support recovery of function after stroke. We have developed a method using vagus nerve stimulation (VNS) paired with motor training to drive robust, specific plasticity in the motor cortex. Our recent studies indicated that VNS paired with rehab training significantly enhances recovery of forelimb function after cortical ischemic stroke. To further the translation potential of our therapy, we accessed the hypothesis that delivering VNS paired with rehab may improve functional recovery in rats that demonstrated chronic forelimb impairments. Methods: All female Sprague Dawley rats were trained on the Isometric Pull Task, which quantifiably measures forelimb force generation. Rats that achieved 5 consecutive days of over 85% hit rate on this task were given a unilateral cortical-subcortical ischemic lesion via injections of a vasoconstrictive peptide, endothelin-1. Following the lesion, rats returned to their home cage, and did not begin rehab training until 5 weeks post-lesion. Upon return, post-lesion forelimb impairment was accessed with the same task parameters used during pre-lesion training, which allowed for a direct comparison of performance. Rats were assigned to balanced treatment groups based on post-lesion baseline hit rate. Treatment groups consisted of VNS delivered during rehab training (Paired VNS; n=10), VNS delivered two hours after rehab training (Delayed VNS; n=10), and rehab training without VNS (Rehab; n=10). Results: At five weeks post-lesion, the unilateral ischemic insult significantly worsened performance in all three groups compared to pre-lesion (Paired VNS: 29.8 ± 5.7%, paired t-test, P < 0.001; Delayed VNS: 24.6 ± 2.7%, P < 0.001; Rehab: 30.4 ± 4.7%, P < 0.001). Following our therapy, the Paired VNS group demonstrated significantly better performance than both control groups (Paired VNS: 81.6 ± 2.3%, P < 0.01; Delayed VNS: 53.2 ± 6.5%, P < 0.01; Rehab: 49.8 ± 6.8%, P < 0.01). Conclusion: Our results indicate that VNS paired with rehab training can further enhance recovery of forelimb function in chronically impaired rats.

2020 ◽  
Author(s):  
Linmei Zheng ◽  
Rong Tang ◽  
Lei Shi ◽  
Mei Zhong ◽  
Zhongyi Zhou

Abstract Background Preeclampsia is characterized by an excessive inflammatory response. Recent studies have shown that vagus nerve stimulation (VNS) has anti-inflammatory properties in vivo. This study aims to investigate whether VNS is safe for use during pregnancy and to explore the therapeutic potential and underlying mechanisms of VNS in PE. Methods Pregnant Sprague-Dawley rats were randomly chosen to receive N-nitro-L-arginine methyl ester (L-NAME)-containing water (preeclampsia-like mouse model) or saline (normal pregnancy control) daily at gestational days 14.5-20.5. VNS and the α7nAChR antagonist methyllycaconitine citrate (MLA, 1 mg/kg/d) were given daily at the same time.Results VNS decreased the high systolic blood pressure and urinary protein observed in the PE rats. In addition, VNS mitigated abnormal pregnancy outcomes. Moreover, VNS alleviated the inflammatory response by decreasing the levels of inflammatory cytokines. VNS significantly increased the expression of α7nAChR and attenuated the activation of NF-κB p65 in the placenta.Discussion Our findings indicate that maternal VNS treatment is safe during pregnancy and has a protective effect in a pregnant rat model of preeclampsia induced by L-NAME.


2018 ◽  
Vol 42 (2) ◽  
pp. 159-165 ◽  
Author(s):  
Michael P. Kilgard ◽  
Robert L. Rennaker ◽  
Jen Alexander ◽  
Jesse Dawson

2014 ◽  
Vol 134 (3) ◽  
pp. 332-337
Author(s):  
Kenichi Usami ◽  
Ryuji Kano ◽  
Kensuke Kawai ◽  
Takahiro Noda ◽  
Tomoyo Isoguchi Shiramatsu ◽  
...  

2016 ◽  
Vol 33 (9) ◽  
pp. 871-879 ◽  
Author(s):  
David T. Pruitt ◽  
Ariel N. Schmid ◽  
Lily J. Kim ◽  
Caroline M. Abe ◽  
Jenny L. Trieu ◽  
...  

2006 ◽  
Vol 23 (10) ◽  
pp. 1549-1560 ◽  
Author(s):  
Douglas C. Smith ◽  
Arlene A. Tan ◽  
Andrea Duke ◽  
Steven L. Neese ◽  
Richard W. Clough ◽  
...  

2021 ◽  
Author(s):  
linmei Zheng ◽  
Rong Tang ◽  
Lei Shi ◽  
Mei Zhong ◽  
Zhongyi Zhou

Abstract Background Preeclampsia is characterized by an excessive inflammatory response. Recent studies have shown that vagus nerve stimulation (VNS) has anti-inflammatory properties in vivo. This study aims to investigate whether VNS is safe for use during pregnancy and to explore the therapeutic potential and underlying mechanisms of VNS in PE. Methods Pregnant Sprague-Dawley rats were randomly chosen to receive N-nitro-L-arginine methyl ester (L-NAME)-containing water (preeclampsia-like mouse model) or saline (normal pregnancy control) daily at gestational days 14.5-20.5. VNS and the α7nAChR antagonist methyllycaconitine citrate (MLA, 1 mg/kg/d) were given daily at the same time. Results VNS decreased the high systolic blood pressure and urinary protein observed in the PE rats. In addition, VNS mitigated abnormal pregnancy outcomes. Moreover, VNS alleviated the inflammatory response by decreasing the levels of inflammatory cytokines. VNS significantly increased the expression of α7nAChR and attenuated the activation of NF-κB p65 in the placenta. Discussion Our findings indicate that maternal VNS treatment is safe during pregnancy and has a protective effect in a pregnant rat model of preeclampsia induced by L-NAME.


2020 ◽  
Author(s):  
Linmei Zheng ◽  
Rong Tang ◽  
Lei Shi ◽  
Mei Zhong ◽  
Zhongyi Zhou

Abstract Background Preeclampsia is characterized by an excessive inflammatory response. Recent studies have shown that vagus nerve stimulation (VNS) has anti-inflammatory properties in vivo. This study aims to investigate whether VNS is safe for use during pregnancy and to explore the therapeutic potential and underlying mechanisms of VNS in PE. Methods Pregnant Sprague-Dawley rats were randomly chosen to receive N-nitro-L-arginine methyl ester (L-NAME)-containing water (preeclampsia-like mouse model) or saline (normal pregnancy control) daily at gestational days 14.5-20.5. VNS and the α7nAChR antagonist methyllycaconitine citrate (MLA, 1 mg/kg/d) were given daily at the same time. Results VNS decreased the high systolic blood pressure and urinary protein observed in the PE rats. In addition, VNS mitigated abnormal pregnancy outcomes. Moreover, VNS alleviated the inflammatory response by decreasing the levels of inflammatory cytokines. VNS significantly increased the expression of α7nAChR and attenuated the activation of NF-κB p65 in the placenta. Discussion Our findings indicate that maternal VNS treatment is safe during pregnancy and has a protective effect in a pregnant rat model of preeclampsia induced by L-NAME.


Sign in / Sign up

Export Citation Format

Share Document